

VICURON PHARMACEUTICALS INC

Form 8-K

July 20, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):**

**July 19, 2004**

---

**Vicuron Pharmaceuticals Inc.**

**(Exact Name of Registrant As Specified in its Charter)**

---

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-31145**  
**(Commission File Number)**

**04-3278032**  
**(I.R.S. Employer**  
  
**Identification Number)**

**455 South Gulph Road, Suite 305, King of Prussia, PA 19406**

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

---

**Item 5. Other Events and Required FD Disclosure.**

On July 19, 2004, Oscient Pharmaceuticals Corporation announced that it closed enrollment in its study of the prevention of vancomycin-resistant enterococci (VRE) bloodstream infections (the so-called RAVE (Ramoplanin Against VRE) trial). Oscient took this action without the consent of Vicuron Pharmaceuticals Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.  
(Registrant)

Date: July 20, 2004

By: /s/ GEORGE F. HORNER III

---

George F. Horner III  
President and Chief Executive Officer